IntelGenx (TSXV:IGX; OTCQB:IGXT) granted cannabinoid-derived drug developer Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) additional exclusive worldwide rights to IntelGenx’s Adversa mucoadhesive delivery technology.
Adversa is designed to limit first-pass metabolism, improve bioavailability, enhance product stability and reduce gastro-intestinal exposure and side-effects.
Tetra will use the Adversa technology to develop a THC-based mucoadhesive film containing its Dronabinol drug candidate for the treatment of chemotherapy-induced nausea and vomiting.
Under the new pact, Tetra is purchasing the worldwide Adversa technology rights as it relates to Dronabinol for three undisclosed milestone payments, with 45% to be paid on each of November 15, 2020 and March 1, 2021 and a final payment of 10% upon successful technology transfer. Tetra also will pay IntelGenx a low single-digit royalty on future net sales of Dronabinol mucoadhesive tablets.
“This agreement reflects the many potential therapeutic benefits of our Adversa delivery technology,” Horst G. Zerbe Ph.D., CEO of IntelGenx, said in a statement.
“In addition to being particularly well-suited for patients who have difficulty swallowing capsules – a common and unfortunate side effect of chemotherapy – Adversa offers comparable efficacy to capsules, with a potentially superior side-effect profile,” he added.
